Conference Reports for NATAP

Back

HIV Drug Therapy Glasgow November 2-6, 2014 Glasgow, UK     HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Subgroup Analysis - (11/18/14)   HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Subgroup Analysis and Safety Profile - oral presentation - (11/18/14)   Phase IIIb, open-label, single-arm trial of darunavir/cobicistat: Week 48 subgroup analysis of HIV-1-infected, treatment-naïve adults - PK/virology/safety/tolerability - (11/18/14)   Week 48 efficacy analysis of the PROTEA trial: darunavir/ritonavir monotherapy versus darunavir/ritonavir with two nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL at baseline - (11/13/14)   Safety Profile of HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Analysis - (11/12/14)   Efficacy of PI monotherapy versus triple therapy for 2202 patients in 12 randomised trials - (11/12/14)   Analysis of neurocognitive function and CNS endpoints in the PROTEA trial: darunavir/ritonavir with or without nucleoside analogues - (11/12/14)   Two Years of Truvada for Pre-Exposure Prophylaxis Utilization in the United States - (11/07/14)   Cobicistat (COBI) in HIV-Infected Patients with Mild to Moderate Renal Impairment - (11/07/14)   Long-Term Efficacy and Safety of E/C/F/TDF vs. EFV/FTC/TDF and ATV+RTV+FTC/TDF in HIV-1-infected Treatment Naïve Subjects Age ≥ 50 Years - (11/07/14)   Renal Safety Profile of STB in Virologically Suppressed Subjects From Two Randomized, Phase 3b Switch Trials - (11/07/14)   Switch to Stribild vs Continuation of NVP or RPV with FTC and TDF in Virologically Suppressed HIV Adults: A STRATEGY-NNRTI Subgroup Analysis - (11/07/14)   Simplification to Stribild vs Continuation of RTV-boosted DRV with FTC and TDF in Virologically Suppressed HIV Adults: A STRATEGY-PI Subgroup Analysis - (11/07/14)   Glasgow: The Effect of Dolutegravir on the Pharmacokinetics of Metformin in Healthy Subjects - (11/06/14)   Glasgow: First Prospective Comparison of Genotypic vs Phenotypic Tropism Assays in Predicting Virologic Responses to Maraviroc (MVC) in a Phase 3 Study: MODERN - (11/06/14)   Glasgow: Patient Preferences for Characteristics of Antiretroviral Therapies: Results From 5 European Countries - (11/06/14)   GLASGOW: Dolutegravir Is Superior to Darunavir/Ritonavir in Treatment-Naive HIV-1 Infected Individuals: 96 Week Results From FLAMINGO - (11/06/14)